In Gleevec Feud, Novartis Targets Indian Patent Rules

Law360, New York (August 18, 2006, 12:00 AM EDT) -- In its ongoing battle to patent its cancer treatment Gleevec in India, Novartis AG has lashed out not only at the rejection of its patent application earlier this year, but at a key section of India’s recently enacted patent laws.

Earlier this week, Novartis filed two petitions with the Madras High Court, railing against the Patent Controller's decision to reject its patent application on the ground that the ruling lacks legal or factual basis. The company is also seeking an interim stay, the Hindu Business Line...
To view the full article, register now.